Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Feb
08
Today In Oncology
A Paradigm Shift In Treating Adult AML?
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo